Hui O. Clausen

Soborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.

Journal: The New England journal of medicine

Published: April 29, 2026

Factor VIII Activity and Factor VIII Inhibitors Can Be Measured Accurately in Plasma Containing Mim8 by Using Specific Chromogenic Assays.

Factor VIII Activity and Factor VIII Inhibitors Can Be Measured Accurately in Plasma Containing Mim8 by Using Specific Chromogenic Assays.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: September 26, 2024

Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.

Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.

Journal: European journal of haematology

Published: January 23, 2023

Measuring factor VIII activity in samples from patients treated with N8-GP (Esperoct® ; turoctocog alfa pegol) during the pathfinder clinical trials programme.

Measuring factor VIII activity in samples from patients treated with N8-GP (Esperoct® ; turoctocog alfa pegol) during the pathfinder clinical trials programme.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 01, 2020

Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience.

Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience.

Journal: Acta haematologica

Published: June 05, 2019

A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.

A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: January 29, 2019

Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.

Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: May 02, 2018

Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol.

Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: August 21, 2017

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: December 23, 2016

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.

Journal: Thrombosis and haemostasis

Published: June 10, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026